222 related articles for article (PubMed ID: 21862685)
1. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.
Waldron NN; Kaufman DS; Oh S; Inde Z; Hexum MK; Ohlfest JR; Vallera DA
Mol Cancer Ther; 2011 Oct; 10(10):1829-38. PubMed ID: 21862685
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
[TBL] [Abstract][Full Text] [Related]
3. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256
[TBL] [Abstract][Full Text] [Related]
4. Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer.
Bera TK; Williams-Gould J; Beers R; Chowdhury P; Pastan I
Mol Cancer Ther; 2001 Dec; 1(2):79-84. PubMed ID: 12467225
[TBL] [Abstract][Full Text] [Related]
5. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
[TBL] [Abstract][Full Text] [Related]
6. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.
Waldron NN; Barsky SH; Dougherty PR; Vallera DA
Target Oncol; 2014 Sep; 9(3):239-49. PubMed ID: 23900680
[TBL] [Abstract][Full Text] [Related]
7. Construction, expression, and characterization of an anti-tumor immunotoxin containing the human anti-c-Met single-chain antibody and PE38KDEL.
Liu Z; Feng Z; Zhu X; Xu W; Zhu J; Zhang X; Fan Z; Ji G
Immunol Lett; 2013 Jan; 149(1-2):30-40. PubMed ID: 23026237
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of CD133+ cells in oral cancer cell lines.
Damek-Poprawa M; Volgina A; Korostoff J; Sollecito TP; Brose MS; O'Malley BW; Akintoye SO; DiRienzo JM
J Dent Res; 2011 May; 90(5):638-45. PubMed ID: 21220361
[TBL] [Abstract][Full Text] [Related]
9. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxin targeting CD133(+) breast carcinoma cells.
Ohlfest JR; Zellmer DM; Panyam J; Swaminathan SK; Oh S; Waldron NN; Toma S; Vallera DA
Drug Deliv Transl Res; 2013 Apr; 3(2):195-204. PubMed ID: 25787984
[TBL] [Abstract][Full Text] [Related]
11. Immunotoxin-mediated targeting of claudin-4 inhibits the proliferation of cancer cells.
Hashimi SM; Yu S; Alqurashi N; Ipe DS; Wei MQ
Int J Oncol; 2013 Jun; 42(6):1911-8. PubMed ID: 23563899
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
13. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
14. Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity.
Stratford EW; Bostad M; Castro R; Skarpen E; Berg K; Høgset A; Myklebost O; Selbo PK
Biochim Biophys Acta; 2013 Aug; 1830(8):4235-43. PubMed ID: 23643966
[TBL] [Abstract][Full Text] [Related]
15. Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells.
Tur MK; Huhn M; Thepen T; Stöcker M; Krohn R; Vogel S; Jost E; Osieka R; van de Winkel JG; Fischer R; Finnern R; Barth S
Cancer Res; 2003 Dec; 63(23):8414-9. PubMed ID: 14679004
[TBL] [Abstract][Full Text] [Related]
16. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
17. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
18. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
19. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
20. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]